Akebia Therapeutics, Inc. (AKBA) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

8/25

Growth 2 Margin 1 Expansion 3 Platform 0 Financial 2

latest quarter score

Earnings Reports

8
Akebia (AKBA) Q2 2026: Vafcio Patients Up 41%, Pipeline Drives Rare Disease Optionality
August 06, 2026
9
Akebia (AKBA) Q1 2026: Vafseo Patient Base Jumps 60% as Observed Dosing Drives Adoption
May 07, 2026
14
Akebia (AKBA) Q4 2025: Vafsio Prescriber Base Expands 5x, Anchoring Dialysis Market Push
February 26, 2026
10
Akebia (AKBA) Q3 2025: Prescribing Access Expands 7x, Setting Up 2026 Inflection
November 10, 2025
21
Akebia (AKBA) Q2 2025: Vafseo Patient Access Doubles, Setting Stage for 275K Prescriber Surge
August 07, 2025
12
Akebia (AKBA) Q1 2025: Vafseo Launch Drives $12M Debut, Setting Up Doubling Patient Access with LDO Rollout
July 06, 2025
10
Akebia Therapeutics (AKBA) Q4 2024: Vafseo Launch Drives Early Momentum with $10-$11M Q1 Revenue Guidance
March 13, 2025
Akebia (AKBA) Q3 2024: Vafcio Contracts Secure 60% Dialysis Access Ahead of January Launch
November 07, 2024
Akebia (AKBA) Q2 2024: 90% Dialysis Market Contracted Ahead of Vafseo Launch
August 08, 2024
Akebia (AKBA) Q1 2024: Field Team Expansion Up 55% Accelerates Vafseo Launch Traction
May 09, 2024
11
Akebia Therapeutics (AKBA) Q3 2023: $18M COGS Decline Extends Cash Runway Ahead of PDUFA Catalyst
November 08, 2023
8
Akebia (AKBA) Q2 2023: 21.6% Sequential Auryxia Revenue Jump Sets Stage for Vatadustat FDA Catalyst
August 25, 2023
Akebia (AKBA) Q1 2023: Operating Expenses Cut 50% as EU Approval Unlocks Vatadustat Path
May 08, 2023
Akebia (AKBA) Q4 2022: Oxbryta Revenue Jumps 25% as EU Vatadustat Decision Nears
March 09, 2023

Browse all companies